MRP2基因单核苷酸多态性对晚期卵巢癌铂类化疗敏感性的影响

被引：3

作者：

杨兴升

关根正幸

仓田仁

田中宪一

机构：

[1] 山东大学齐鲁医院

[2] 日本新渇大学

[3] 日本新渇大学山东济南

来源：

实用妇产科杂志 | 2004年 / 03期

关键词：

卵巢癌; MRP2基因; 基因多态性; 耐药性; 顺铂;

D O I：

暂无

中图分类号：

R737.31 [卵巢肿瘤];

学科分类号：

100214 ;

摘要：

目的 :探讨MRP2基因单核苷酸多态性与晚期卵巢癌对铂类化疗敏感性的关系。方法 :本研究包括 89例晚期卵巢癌患者 ,其中Ⅲ期 77例 ,Ⅳ期 12例。所有患者均行肿瘤细胞减灭术 ,术后常规化疗 6～ 8疗程 ,均用顺铂加紫杉醇及其他药物化疗。 89例患者中 ,完全缓解 (CR)或部分缓解 (PR) 6 2例 ,肿瘤无变化 (NC)或进展 (PD) 2 7例。采用单核苷酸延伸技术 ,检测肿瘤组织中MRP2基因促进子 (C 2 4T)、第 10外显子 (G12 4 9A)及第 2 8外显子 (C3972T)的单核苷酸多态性。观察其对铂类化疗敏感性的影响。结果 :MRP2基因促进子及第 2 8外显子单核苷酸多态性对卵巢癌患者对铂类化疗反应无明显影响 ,而MRP2基因第 10外显子突变型与铂类化疗敏感性密切相关 (P <0 0 5 )。结论 :MRP2基因第 10外显子单核苷酸多态性影响晚期卵巢癌患者对铂类化疗的敏感性

引用

页码：153 / 155

页数：3

共 13 条

[1]

Polymorphism in human CYP2C* decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Dai D,Zeldin DC,Blaisdell JA,et al. Pharmacogenetics . 2001

[2]

Polymorphism of the ABC transporter genes,MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Ito S,Ieiri I,Tanabe M,et al. Pharmacogenetics . 2001

[3]

Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Suzuki H and Sugiyama Y. Advanced Drug Delivery Reviews . 2002

[4]

Hepatic secretion of conjugated drugs and endogenous substances. Keppler D,Konig J. Seminars in Liver Disease . 2000

[5]

Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2,permanently expressed in human and canine cells. Cui Y,Konig J,Buchholz JK,et al. Molecular Pharmacology . 1999

[6]

Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2. Ito K,Suzuki H,Sugiyama y. Molecular Pharmacology . 2001

[7]

Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Sparreboom A,Danesi R,Ando Y,et al. Drug Resistance Updates . 2003

[8]

Transport of glutathione conjugates and glucronides by the multidrug resistance proteins MRP1 and MRP2. Keppler D,Leier I,Jedlitschky G. Biological Chemistry . 1997

[9]

Canalicular multispecific organic anion transporter( cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Koike K,Kawabe T,Tanaka T,et al. Cancer Research . 1997

[10]

The use of single-nucleotide polymorphism maps in pharmacogenomics. McCarthy JJ,Hilfiker R. Nature Biotechnology . 2000

← 1 2 →